Wissam A Jaber
@wissamj123
Followers
1K
Following
284
Media
15
Statuses
73
Emory University; Cath Lab Director; Interv cards fellowship director; CTO; pulmonary embolism
Atlanta, GA
Joined May 2014
Trainees, ready to lead in VTE care? Applications for the PERT Trainee Council open on January 6! Collaborate, plan, and make a difference in your field. Apply: Jan 6 – Apr 1, 2025 Details: https://t.co/6xMwhtzLSN
@RosovskyRachel
@AWitkin
@wissamj123
@FMaeWestMD
0
4
15
Webinar on November 12: Join us for The Clinical PE Story: PEERLESS RCT Comparing FlowTriever to CDT, an in-depth discussion on the PEERLESS randomized controlled trial results. This session will explore the RCT outcomes and offer valuable clinical insights into the future of PE
0
2
16
#SimPub #CircTCT24 PEERLESS Randomized Control Trial: in patients with acute intermediate-risk pulmonary embolism (PE), large-bore mechanical thrombectomy (LBMT) significantly reduced adverse outcomes, comparted with catheter-directed thrombolysis (CDT) https://t.co/8fFIOReW9D
2
24
45
At Emory, always pushing the boundaries of innovation! TCT2024 live case. First-in-man electrosurgical mitral commissurotomy (CLEFT). Novel approach for mitral stenosis with high Wilkins score and prohibitive surgical risk #TCT2024 @AdamGreenbaumMD @BabaliarosArgos @acamajmd
8
39
126
Be among the first to discover groundbreaking science! 🔍 Dr. @wissamj123 previews the eagerly awaited PEERLESS trial to be revealed on Tuesday, October 29 at #TCT2024. 💡 This is your opportunity to stay ahead of the curve with innovations that could revolutionize
0
22
53
The 2024 BPA-CTEPH Alliance Conference is on Wednesday, September 11. This event is dedicated to fostering collaboration among practitioners and researchers in the specialized fields of BPA-CTEPH. https://t.co/zcDh9m6tuL
@rchannick
@krosenfieldMD
@CutticaMike
@wissamj123
0
3
4
Join us at #TCT2024 for the late-breaking #PEERLESS RCT data release! PEERLESS is a randomized trial comparing the #FlowTriever System vs catheter-directed thrombolysis (CDT) for the treatment of intermediate-high risk PE. @wissamj123
#TCT2024 Late-Breaking Research Announced! 🚨 🌟 The moment you’ve been waiting for is here! Discover game-changing research that will revolutionize cardiovascular care. Get ready to witness the breakthroughs that will transform your practice and redefine patient outcomes. 🚀
0
11
23
3 days and counting - Join us for a comprehensive dive into pulmonary embolism science, from diagnosis to intervention. Connect with peers, share insights, and drive the future of PE care. See you there: https://t.co/QaKDH4OZ0f
#PERT2024
@rchannick
@krosenfieldMD
@wissamj123
0
4
11
I just became an official #PERTMember! Learn more and join today: https://t.co/RyTGj1CV1j #JoinPERT @ThePERTConsortium
0
1
16
EPIC 2024, April 18-19 #EmoryPercutaneousInterventionCourse #Cardiology #Cardiologists #cardiovascular #Medinbox #WondrMedical #coronary #StructuralHeart #Interventional #EPIC2024 For EPIC 2024 Registration options and other information please click here: https://t.co/GOkKHxVAXg
0
7
11
Great panel and operators for the first CTO case @DrBillLombardi @leahmraj @wjn_md Kevin Croce, Nik Lembo, Jay Khatri, Toni Demartini, Simon Walsh @EpicSec
0
0
2
Legendary Dr John Webb delivering his keynote speech at Emory Interventional Course https://t.co/9p7oW96Qn9 Join to watch 12 of the most complex coronary and structural live cases today and tomorrow
1
0
26
Just published in @CircAHA CI: the latest evidence in the treatment of high-risk PE 🔥#FLAME is the largest prospective study of interventional treatment in #highriskPE. This #datamatters 🧵 https://t.co/5IGeSXscFZ
#MitchSilver @CMichaelGibson @jaygirimd #SameerKhandar
9
87
210
Another great CTO live course at Emory. Thanks to Medtronic for support and the wonderful staff and faculty. @wjn_md @MDT_Cardiac @PSandesara_MD @RinfretStephane
2
2
50
Another great Emory interventional fellowship year. Congratulations to our amazing fellows! @PSandesara_MD @wjn_md @RinfretStephane @ChangeAtHeart @JCL3MD @drdevireddy
2
5
53
As the latest representation of Inari's commitment to clinical evidence, we are proud to share the planned enrollment of the #PEERLESS II trial, a prospective, global, multi-center RCT comparing the outcomes of #PE patients treated with the #FlowTriever system vs #anticoagulation
2
41
91
So happy the finally see the needle changing on the treatment of the massive PE population!
NOW at #ACC2023
#FLAME high-risk #PE registry results 🔥@InariMedical FT pts w 1.9% in-hospital mortality 🔥Context arm consistent w hx data 29.5% in-hospital mortality 🔥Trial stopped early due 2 overwhelmingly meeting pre-defined PGs @ interim Unheard of. Practice changing
0
3
30
Very proud of our research intern Malika @MalikaElhHassan presenting the Emory experience on LM PCI with calcium modification at ACC23 @PSandesara_MD @EmoryDeptofMed
2
4
50